Patterns of use of long-acting bronchodilators in patients with COPD: A nationwide follow-up study of new users in New Zealand

Respirology ◽  
2017 ◽  
Vol 23 (6) ◽  
pp. 583-592 ◽  
Author(s):  
Lianne Parkin ◽  
David Barson ◽  
Jiaxu Zeng ◽  
Simon Horsburgh ◽  
Katrina Sharples ◽  
...  
2021 ◽  
Author(s):  
Jorge Machado Alba

Introduction: Chronic obstructive pulmonary disease (COPD) affects approximately 174 million people worldwide.The objective was to determine the trends of the use of medications for COPD in a group of Colombian patients. Methods: This was a retrospective study on prescription patterns of bronchodilators and other medications used in COPD from a population database with follow-up at 12 and 24 months. Patients older than 18 years of age of any sex who had COPD between 2017 and 2019 were included. Sociodemographic variables, medications, treatment schedules for COPD, comorbidities, comedications, and the specialty of the prescriber were considered. Results: A total of 9,476 people with a diagnosis of COPD were evaluated. They had a mean age of 75.9 ± 10.7 years, 50.1% were men, and 86.8% were prescribed by a general practitioner. At the beginning of the follow-up, on average, they received 1.6 medications/patient, mainly short-acting antimuscarinics (3784; 39.9%), followed by short-acting β-agonists (2997, 31.6%) and inhaled corticosteroids (ICS) (2239, 23.6%), but 5083 (53.6%) patients received a long-acting bronchodilator. At the beginning of the follow-up, 645 (6.8%) patients were put on triple therapy with antimuscarinics, β-agonists, and ICS, and at 12 months, this rose to 1388 (20.6%). A total of 57.9% had comorbidities, most often hypertension (44.4%). Conclusions: This group of patients with COPD treated in Colombia frequently received short-acting bronchodilators and ICS, but a growing proportion are undergoing controlled therapy with long-acting bronchodilators, a situation that can improve the indicators of morbidity, exacerbations, and hospitalization.


1976 ◽  
Vol 128 (3) ◽  
pp. 246-250 ◽  
Author(s):  
D. A. W. Johnson

SummaryThe results from a prospective follow-up study of a group of schizophrenic patients suggest that a significant proportion (41 per cent) are likely to relapse during a two-year period despite the prescription of long-acting injectable neuroleptic drugs. Some will relapse because of a failure of the regime, but others (32–37 per cent) because the pharmacological protection of these drugs would appear to be less effective in certain patients. Even with the major advantages of the long-acting injectable neuroleptics over oral medication, the schizophrenic patient population remains a group with a high incidence of psychiatric and social morbidity which continues to require the full resources of both the hospital and community services.


2009 ◽  
Vol 15 (4) ◽  
pp. 281-281 ◽  
Author(s):  
D Begg ◽  
J Langley ◽  
J Broughton ◽  
R Brookland ◽  
S Ameratunga ◽  
...  
Keyword(s):  

2009 ◽  
Vol 15 (4) ◽  
pp. e2-e2 ◽  
Author(s):  
D Begg ◽  
J Langley ◽  
J Broughton ◽  
R Brookland ◽  
S Ameratunga ◽  
...  
Keyword(s):  

Author(s):  
Milou Cecilia Madsen ◽  
Dennis van Dijk ◽  
Chantal Maria Wiepjes ◽  
Elfi Barbara Conemans ◽  
Abel Thijs ◽  
...  

Abstract Context Erythrocytosis is a known side effect of testosterone therapy that can increase the risk of thromboembolic events. Objectives To study the prevalence and determinants in the development of erythrocytosis in trans men using testosterone. Design A twenty year follow-up study in adult trans men who started testosterone therapy, and had monitoring of hematocrit at our center (n=1073). Results Erythrocytosis occurred in 11% (hematocrit>0.50 l/l), 3.7% (hematocrit>0.52 l/l) and 0.5% (hematocrit>0.54 l/l) of trans men. Tobacco use (OR 2.2, 95%CI 1.6-3.3), long-acting undecanoate injections (OR 2.9, 95%CI 1.7-5.0), age at initiation of hormone therapy (OR 5.9, 95%CI 2.8-12.3), BMI (OR 3.7, 95%CI 2.2-6.2) and pulmonary conditions associated with erythrocytosis and polycythemia vera (OR 2.5, 95%CI 1.4-4.4) were associated with hematocrit >0.50 l/l. In the first year of testosterone therapy hematocrit increased most: 0.39 l/l at baseline to 0.45 l/l after 1 year. Although there was only a slight continuation of this increase in the following 20 years, the probability of developing erythrocytosis still increased (10% after 1 year, 38% after 10 years). Conclusion Erythrocytosis occurs in trans men using testosterone. The largest increase in hematocrit was seen in the first year, but also after the first years there is a substantial number of people that present with hematocrit >0.50 l/l. A reasonable first step in the care for trans men with erythrocytosis while on testosterone is to advise them to quit smoking and to switch to a transdermal administration route and if BMI is high, to lose weight.


2006 ◽  
Vol 27 (2) ◽  
pp. 141-146 ◽  
Author(s):  
Gulden Pasaoglu ◽  
Haydar Gok ◽  
Dilsad Mungan ◽  
Birkan Sonel ◽  
Peyman Yalcin ◽  
...  

2009 ◽  
Vol 13 (4) ◽  
pp. 298-302 ◽  
Author(s):  
Paul N. Deslandes ◽  
Anna Lewis ◽  
Arwel Thomas ◽  
Robert D.E. Sewell
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document